Effects of LP28 on Immunity Enhancement in the Elderly
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Han-Yin Hsu
- Phone Number: +886-07-6955680 Ext. 553
- Email: hanin@synbiotech.com.tw
Study Contact Backup
- Name: Chia-Chia Lee, PhD
- Phone Number: +886-07-6955680 Ext. 550
- Email: cclee@synbiotech.com.tw
Study Locations
-
-
-
Taichung, Taiwan, 407219
- Taichung Veterans General Hospital
-
Taichung, Taiwan, 402202
- National Chung Hsing University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Those who had symptoms of common cold or tonsillitis at least twice in the past year.
Exclusion Criteria:
- People who have liver, kidney, immune, or neoplastic diseases diagnosed by doctor.
- People with mental illnesses such as schizophrenia or depression.
- People who have allergic rhinitis.
- People who have a current condition of drug or alcohol dependence.
- Any person is deemed inappropriate by the researcher for the clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LP28 capsule
Subjects will take two capsule of the experimental group(LP28 capsule) within 30 minutes before breakfast and dinner each day.
|
LP28 capsule : 5.0×10^9 CFU/capsule
|
|
Placebo Comparator: Placebo capsule
Subjects will take two placebo capsule within 30 minutes before breakfast and dinner each day.
|
Maltodextrin
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
WURSS-24
Time Frame: From enrollment to the end of treatment at 12 weeks (measure daily)
|
The WURSS-24 (Wisconsin Upper Respiratory Symptom Survey-24) is a questionnaire designed to assess the impact of upper respiratory tract infections, such as the common cold, on daily life and health.
It includes 24 questions covering symptoms (e.g., cough, runny nose, fatigue) and how they affect daily activities, work, and social interactions.
Patients rate each item on a scale from 0 (no problem) to 7 (severe problem).
|
From enrollment to the end of treatment at 12 weeks (measure daily)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immune cell ratio
Time Frame: From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
|
Blood samples were collected, and the proportions of immune cells were analyzed using flow cytometry, including: (1) CD3+/lymphocyte, (2) CD4+/CD3+, (3) CD8+/CD3+, and (4) CD56+CD16+/lymphocyte.
|
From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
|
|
NK cell activity
Time Frame: From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
|
Peripheral blood mononuclear cells (PBMCs) were isolated, and magnetic bead-based separation was used to deplete non-NK cells.
The K562 human immortalized myelogenous leukemia cell line was then used as target cells, and the proportion of K562 cells lysed by NK cells was measured as an indicator of NK cell activity.
|
From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
|
|
Cytokines measurement
Time Frame: From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
|
Plasma was collected, and cytokine concentrations were analyzed using enzyme-linked immunosorbent assay (ELISA).
The detection items included IL-4, IL-6, IL-12, IFN-γ, CRP and TNF-α.
|
From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
|
|
sIgA
Time Frame: From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
|
Saliva samples were collected, and Secretory immunoglobulin A (sIgA) concentrations were analyzed using enzyme-linked immunosorbent assay (ELISA).
|
From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
|
|
α-amylase
Time Frame: From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
|
Saliva samples were collected, and α-amylase concentrations were analyzed using enzyme-linked immunosorbent assay (ELISA).
|
From enrollment to the end of treatment at 12 weeks (measure every 6 weeks)
|
|
GSRS questionnaire
Time Frame: From enrollment to the end of treatment at 12 weeks (measure weekly)
|
The Gastrointestinal Symptom Rating Scale (GSRS) is a questionnaire used to evaluate the severity of gastrointestinal symptoms.
It includes questions on five key areas: abdominal pain, reflux, diarrhea, indigestion, and constipation.
Patients rate their symptoms on a 7-point Likert scale, where higher scores indicate more severe symptoms.
|
From enrollment to the end of treatment at 12 weeks (measure weekly)
|
|
Defecation frequency and stool pattern
Time Frame: From enrollment to the end of treatment at 12 weeks (measure weekly)
|
Defecation frequency was recorded, and stool characteristics, including shape, consistency, and color, were documented using the Bristol Stool Chart.
|
From enrollment to the end of treatment at 12 weeks (measure weekly)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SF24108C
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.